The United States Food and Drug Administration (FDA) issued a warning in 2011 that the surgical placement of transvaginal mesh devices for the healing of Pelvic Organ Prolapse (POP) poses a greater risk to users than other surgical options. The warning indicated that most POP cases can be cured with less invasive procedures, such as stitches, and that there is no evidence that the vaginal mesh device offers an improved quality of life. In spite of the fact that the warning indicated that surgical mesh is a permanent procedure, and can make any future procedures more complicated, doctors continued to use the procedure. The FDA approved the use of mesh for transvaginal surgeries in 1996 after a mesh was developed by Boston Scientific. By 2010, four types of vaginal mesh devices entered the market; the most widespread in a non-absorbable polyester, while others include absorbable polyester, synthetic mesh, and animal tissue mesh. In that year alone, the FDA reports that at least 100,000 POP repairs using mesh were conducted, with about 75% of those being transvaginal. However new lawsuits against the makers of transvaginal mesh are reporting that not only does the device pose significant health risks, but in fact can cause the POP to reoccur in patients.
What is Pelvic Organ Prolapse (POP)?POP is a condition where some pelvic organ prolapses (plunges) from its natural position and falls against the walls of the vagina. These organs can include the:
- Small bowel